Main Article Content

Gabriel Aníbal Hugo Merino
José Enrique Bombón Chico
Gabriela Alejandra Díaz Terán
Edison Iván Martínez Anancolla
Darwin Giancarlo Tobar Vallejo
Lisseth Paola Uruchima Romero

Microscopic polyangiitis can manifest with such broad clinical heterogeneity that its early identification requires an integrative and critical interpretation of the initial symptoms. We present the case of a 68-year-old man whose illness began in an unusual manner: ascending weakness, neuropathic pain, and progressive hypoesthesia, a presentation that mimicked Guillain-Barré syndrome and initially led investigators to consider a demyelinating neuropathy. However, alongside this apparent neurological origin, subtle but decisive indicators emerged: intermittent fever, malaise, hematuria, proteinuria, hypoalbuminemia, and an intense inflammatory response, revealing a systemic process not attributable to an isolated neurological disease. Chest CT showed subpleural micronodules and bronchiectasis, while serology revealed low-titer antineutrophil cytoplasmic antibodies with a slightly elevated anti-MPO level—a modest serological profile, but clinically relevant in the presence of renal damage. The renal biopsy resolved the diagnostic dilemma by demonstrating pauci-immune necrotizing glomerulonephritis, confirming microscopic polyangiitis as the unifying cause of the multisystemic presentation. Early treatment with methylprednisolone and cyclophosphamide allowed for the progressive recovery of muscle strength, reduction of neuropathic pain, and stabilization of renal function, underscoring that time is a critical determinant in these vasculitides. This case demonstrates how microscopic polyangiitis can present masked as a primary neurological disorder and highlights the need to integrate clinical, serological, radiological, and histopathological data to coherently reconstruct the diagnosis and avoid potentially irreversible delays.

La poliangeítis microscópica puede manifestarse con una heterogeneidad clínica tan amplia que su identificación temprana exige una lectura integradora y crítica de los primeros síntomas. Presentamos el caso de un hombre de 68 años cuya enfermedad inició de manera inusual: debilidad ascendente, dolor neuropático e hipoestesia progresiva, un cuadro que imitaba un síndrome de Guillain-Barré y orientó inicialmente el abordaje hacia una neuropatía desmielinizante. No obstante, junto a ese aparente origen neurológico emergieron indicadores sutiles pero decisivos: fiebre intermitente, malestar general, hematuria, proteinuria, hipoalbuminemia e intensa respuesta inflamatoria que revelaban un proceso sistémico no atribuible a una enfermedad neurológica aislada. La tomografía de tórax evidenció micronódulos subpleurales y bronquiectasias, mientras que la serología mostró anticuerpos anticitoplasma de neutrófilo en baja titulación con anti-MPO discretamente elevado, un perfil serológico modesto, pero clínicamente relevante en presencia de daño renal. La biopsia renal resolvió el dilema diagnóstico al demostrar una glomerulonefritis necrotizante pauciinmune, confirmando poliangeítis microscópica como la causa unificadora del cuadro multisistémico. El tratamiento temprano con metilprednisolona y ciclofosfamida permitió la recuperación progresiva de la fuerza muscular, la reducción del dolor neuropático y la estabilización de la función renal, subrayando que el tiempo es un determinante crítico en estas vasculitis. Este caso demuestra cómo la poliangeítis microscópica puede presentarse enmascarada como un trastorno neurológico primario y destaca la necesidad de integrar datos clínicos, serológicos, radiológicos e histopatológicos para reconstruir coherentemente el diagnóstico y evitar retrasos potencialmente irreversibles.

Downloads

Download data is not yet available.

Article Details

How to Cite
Hugo Merino, G. A. ., Bombón Chico, J. E. ., Díaz Terán, G. A. ., Martínez Anancolla, E. I. ., Tobar Vallejo, D. G. ., & Uruchima Romero, L. P. . (2025). Vasculitic neuropathy mimicking Guillain-Barré syndrome: initial manifestation of Microscopic Polyangiitis. Revista Vive, 8(24), 1304–1315. https://doi.org/10.33996/revistavive.v8i24.451
Section
INVESTIGACIONES
Referencias

Hellmich B, Sanchez-Alamo B, Schirmer J, Berti A, Blockmans D, Cid M, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Annals of the Rheumatic Diseases. 2024;83(1):30-47. https://ard.bmj.com/content/83/1/30

Duarte A, Ribeiro R, Macedo A, Santos M. ANCA-associated vasculitis: overview and practical issues of diagnosis and therapy from a European perspective. Porto Biomed J. 2023;8(6):e237. DOI: 10.1097/j.pbj.0000000000000237

Lubas A, Staszewski J, Maliborski A, Mosakowska M, Spłocharski G, Bilbin-Bukowska A, et al. Vascular and Vasogenic Manifestations of Systemic ANCA-Associated Vasculitis with Renal Involvement in Non-Contrast Brain MRI in Patients with Acute Disease Onset. Journal of Clinical Medicine 2022;11(16). https://www.mdpi.com/2077-0383/11/16/4863

Koike H, Nishi R, Ohyama K, Morozumi S, Kawagashira Y, Furukawa S, et al. ANCA-Associated Vasculitic Neuropathies: A Review. Neurol Ther. 2022;11(1):21-38. DOI: 10.1007/s40120-021-00315-7

Ginsberg L. Vasculitis and the peripheral nervous system. Rheumatology (Oxford). 2020;59(Supplement_3):iii55-9. DOI: 10.1093/rheumatology/keaa075

Mansueto G, Lanza G, Falleti J, Orabona P, Alaouieh D, Hong E, et al. Central and Peripheral Nervous System Complications of Vasculitis Syndromes from Pathology to Bedside: Part 2—Peripheral Nervous System. Curr Neurol Neurosci Rep. 2023;23(3):83-107. DOI: 10.1007/s11910-023-01249-3

Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Therapeutic Advances in Musculoskeletal. 2015;7(2):45-55. DOI: 10.1177/1759720X14566617

Munagama C, Wathurapatha W, Rajendiran V, Silva S. A Rare Presentation of Non-systemic Vasculitic Neuropathy Mimicking Guillain-Barré Syndrome: A Case Report. Cureus. 16(2):e54945. DOI: 10.7759/cureus.54945

Chapter 42 Specific painful neuropathies. En: Handbook of Clinical Neurology. Elsevier; 2006; 635-52. https://www.sciencedirect.com/science/chapter/handbook/abs/pii/S0072975206800461

Budhu J. Nonsystemic Vasculitic Neuropathy Masquerading as Guillain-Barre Syndrome (5338). Neurology. 2020;94(15_supplement):5338. https://doi.org/10.1212/WNL.94.15_supplement.5338

Watanabe H, Ishizuka K, Hiida M, Ie K, Okuse C. Progressive Purpura in Microscopic Polyangiitis: A Case Report. Cureus. 17(9):e93569. DOI: 10.7759/cureus.93569

Collins M, Dyck J, Gronseth G, Guillevin L, Hadden D, Heuss D, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. Journal of the Peripheral Nervous System. 2010;15(3):176-84. DOI: 10.1111/j.1529-8027.2010.00281.x

Vital C, Vital A, Canron M, Jaffré A, Viallard J, Ragnaud J, et al. Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases. Journal of the Peripheral Nervous System. 2006;11(1):20-9. DOI: 10.1111/j.1085-9489.2006.00060.x

Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman GS, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine. 2010;363(3):221-32. DOI: 10.1056/NEJMoa0909905

Sanchez-Alamo B, Schirmer J, Hellmich B, Jayne D, Monti S, Tomasson G, et al. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV. RMD Open. 2023;9(2):e003083. DOI: 10.1136/rmdopen-2023-003083

Morales E, Rúa-Figueroa I, Callejas Rubio J, Ávila Bernabéu A, Blanco Alonso R, Cid Xutgla M, et al. Recomendaciones para el diagnóstico y tratamiento de las vasculitis asociadas a anticuerpos anticitoplasma de neutrófilo. Nefrología. 2025;45(1):15-58. DOI: 10.1016/j.nefro.2024.07.004

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Annals of the Rheumatic Diseases. 2007;66(2):222-7. doi: 10.1136/ard.2006.054593.

Ross C, Makhzoum JP, Pagnoux C. Updates in ANCA-associated vasculitis. EJR. 2022;9(3):153-66. DOI: 10.5152/eurjrheum.2015.0043

Villiger P, Guillevin L. Microscopic polyangiitis: Clinical presentation. Autoimmunity Reviews. 2010;9(12):812-9. doi: 10.1016/j.autrev.2010.07.009.

Chevet B, Cornec D, Casal Moura M, Cornec-Le Gall E, Fervenza F, Warrington K, et al. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. Rheumatology.2023;62(5):1787-803. doi: 10.1093/rheumatology/keac623.

Hellmich B, Sanchez-Alamo B, Schirmer J, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Annals of the Rheumatic Diseases. 2024;83(1):30-47. https://doi.org/10.1136/ard-2022-223764

Tedesco M, Gallieni M, Pellegata F, Cozzolino M, Alberici F. Update on ANCA-associated vasculitis: from biomarkers to therapy. J Nephrol. 2019;32(6):871-82. DOI: 10.1007/s40620-019-00628-9

Koike H, Nishi R, Ohyama K, Morozumi S, Kawagashira Y, Furukawa S, et al. ANCA-Associated Vasculitic Neuropathies: A Review. Neurol Ther. 2022;11(1):21-38. https://www.journals.vu.lt/neurologijos_seminarai/en/article/view/33567

Roque-Poma M, Ruiz-Marmolejo L, Rojas-Puertas M, Camargo-Espinoza C, Tinoco-Solorzano A. Neuropatía periférica como manifestaciónunica de poliangeítis microscópica en la altura. Reporte de caso. Rev Neuropsiquiatr. 2020;83(2):123-6. DOI: https://doi.org/10.20453/rnp.v83i2.3755

Al-Soudi A, Vegting Y, Klarenbeek P, Hilhorst M. Do Relapses Follow ANCA Rises? A Systematic Review and Meta-Analysis on the Value of Serial ANCA Level Evaluation. Front Med. 2022;9:844112. doi: 10.3389/fmed.2022.844112

Merindol J, Levraut M, Seitz-Polski B, Morand L, Martis N. Diagnostic significance of antineutrophil cytoplasmic antibody (ANCA) titres: a retrospective case-control study. RMD 2023;9(2):e003113. doi: 10.1136/rmdopen-2023-003113.

Chen M, Kallenberg G, Zhao M. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol. 2009;5(6):313-8. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol. doi: 10.1159/000541792

Konstantouli A, Lioulios G, Stai S, Moysidou E, Fylaktou A, Papagianni A, et al. Type of ANCA May Be Indispensable in Distinguishing Subphenotypes of Different Clinical Entities in ANCA-Associated Vasculitis. Life. 2022;12(10):1467. doi: 10.3390/life12101467.

Walker B, Peterson L, Koening C, White S, Schmidt R, Tebo A. Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: A systematic review and meta-analysis. Autoimmunity Reviews. 2022;21(6):103100. DOI: 10.1016/j.autrev.2022.103100

Aasarød K, Bostad L, Hammerstrøm J, Jørstad S, Iversen B. Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrology Dialysis Transplantation. 2001;16(5):953-60. DOI: 10.1093/ndt/16.5.953

Casal Moura M, Fervenza F, Specks U, Sethi S. Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation. 2022;37(9):1710-21. DOI: 10.1093/ndt/gfab250

Geetha D, Jefferson J. ANCA-Associated Vasculitis: Core Curriculum 2020. American Journal of Kidney Diseases. 2020;75(1):124-37. DOI: 10.1053/j.ajkd.2019.04.031

Yaseen K, Mandell B. ANCA associated vasculitis (AAV): a review for internists. Postgraduate Medicine. 2023;135(sup1):3-13. DOI: 10.1080/00325481.2022.2102368

Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases. 2016;75(9):1583-94. https://doi.org/10.1136/annrheumdis-2016-209133

Harper L, Morgan M, Walsh M, Hoglund P, Westman K, Flossmann O, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the Rheumatic Diseases. 2012;71(6):955-60. doi: 10.1136/annrheumdis-2011-200477

Floege J, Jayne R, Sanders S, Tesar V, Rovin B. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis. Kidney International. 2024;105(3):S71-116. doi: 10.1016/j.kint.2023.10.008.

Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 2010;363(3):221-32. doi: 10.1056/NEJMoa0909905

Smith R, Jones R, Specks U, Bond S, Nodale M, Aljayyousi R, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases. 2020;79(9):1243-9. doi: 10.1136/annrheumdis-2019-216863.

Specks U, Merkel P, Seo P, Spiera R, Langford C, Hoffman G, et al. Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. N Engl J Med. 2013;369(5):417-27. Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Annals of the Rheumatic Diseases. 2018;77(8):1143-9. doi: 10.1136/annrheumdis-2017-212878.

Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert W, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Annals of the Rheumatic Diseases. 2017;76(10):1662-8. DOI: 10.1136/annrheumdis-2017-211123

Kitching A, Anders HJ Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71. https://www.ncbi.nlm.nih.gov/books/NBK554372/

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the Rheumatic Diseases. 2009;68(12):1827-32. DOI: 10.1136/ard.2008.101279